New Releases from NCBI BookshelfFruquintinib (Fruzaqla): Indication: For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF agent; an anti-EGFR agent (if RAS wild-type); and either trifluridine-tipiracil or regorafenib: Reimbursement Recommendation [Internet].​Fruquintinib (Fruzaqla): Indication: For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF agent; an anti-EGFR agent (if RAS wild-type); and either trifluridine-tipiracil or regorafenib: Reimbursement Recommendation [Internet].